



## Teleflex to focus on showcasing its Emergency Medicine portfolio at ERC 2015 - European Resuscitation Council, October 29 to 31, 2015 in Prague, Czech Republic, which revolves around the recently released European Resuscitation Guidelines

October 28, 2015

WAYNE, Pa.--(BUSINESS WIRE)--Oct. 28, 2015-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, is committed to connecting clinicians with technology in a way that improves clinical practice and advances patient outcomes. Teleflex will showcase its broad portfolio of products for the field of emergency medicine at the ERC European Resuscitation Council, to be held in Prague, Czech Republic on October 29-31, 2015.

During the event, Teleflex will highlight its range of innovative solutions for intraosseous vascular access, rescue airway, atomization and intubation needs. This includes the Arrow<sup>®</sup> EZ-IO<sup>®</sup> Intraosseous Vascular Access System, the LMA Supreme<sup>®</sup> Airway, as well as the LMA<sup>®</sup> MAD Nasal<sup>™</sup> Intranasal Mucosal Atomization Device. Teleflex will also be hosting several in-booth scenario workshops.

The Arrow<sup>®</sup> EZ-IO<sup>®</sup> Intraosseous Vascular Access System from Teleflex is a complete solution for rapid vascular access – whether the emergency responder is facing difficult vascular access challenges or the need for fast intraosseous access for critical situations and life-threatening emergencies. This system is designed to provide the medical professional vascular access to the central circulation system within seconds<sup>1</sup>, delivering medications, intravenous fluids and blood products to adult and pediatric patients alike.

The LMA Supreme<sup>®</sup> Airway is a laryngeal mask offering a safe and effective option for establishing an emergency airway. Featuring a built-in drain tube to channel gastric secretions away from the airway, the LMA Supreme<sup>®</sup> Airway is an ideal choice for patients undergoing certain procedures requiring mechanical ventilation in the field.

Another featured product will be the LMA<sup>®</sup> MAD Nasal<sup>™</sup> Intranasal Mucosal Atomization Device from Teleflex. When IV drug delivery is less than ideal the LMA<sup>®</sup> MAD Nasal<sup>™</sup> Device<sup>2</sup> can come to the rescue delivering safe, painless and rapidly effective treatment. No needle. No trauma. No risk of needle stick injury.

The Teleflex Clinical & Medical Affairs team will be on hand to conduct scenario based resuscitation scenarios on high fidelity simulation models. The team of highly experienced clinicians from across Europe and the United States will lead scenarios focusing on providing the latest, evidence based interventions related to intraosseous needle placement, intranasal medication delivery, supraglottic airway placement, direct as well as video laryngoscopy. These interactive sessions will help educate clinicians from around Europe, advancing clinical practice and improving patient outcomes.

### About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people's lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit [teleflex.com](http://teleflex.com).

Teleflex is the home of Arrow<sup>®</sup>, Deknatel<sup>®</sup>, Hudson RCI<sup>®</sup>, LMA<sup>®</sup>, Pilling<sup>®</sup>, Rusch<sup>®</sup> and Weck<sup>®</sup> – trusted brands united by a common sense of purpose.

### Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

*Teleflex, the Teleflex logo, Arrow, Deknatel, EZ-IO, Hudson RCI, LMA, LMA Supreme, MAD Nasal, Pilling, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. © 2015 Teleflex Incorporated. All rights reserved.*

### References:

1. Von Hoff DD , Kuhn JG, Burris HA, Miller LJ. Does intraosseous equal intravenous? A pharmacokinetic study. Amer J Emerg Med 2008;26:31-8
2. For use with drugs approved for intranasal delivery

View source version on businesswire.com: <http://www.businesswire.com/news/home/20151028005047/en/>

Source: Teleflex Incorporated

Teleflex Incorporated  
Jake Elguicze  
Treasurer and Vice President, Investor Relations  
610-948-2836

or  
Martina Teichmann-Zindler  
Director Marketing Communications International  
+49 (0)7151-406-538  
[martina.teichmann@teleflex.com](mailto:martina.teichmann@teleflex.com)